BACKGROUND AND OBJECTIVES: An HLA-mismatched donor and a T-cell-depleted graft are known risk factors for Epstein-Barr virus (EBV) reactivation after stem cell transplantation. We studied the frequency and outcome of serum EBV DNA levels in patients transplanted with an unmanipulated graft from an HLA-identical donor. DESIGN AND METHODS: Overall, 5479 serial serum samples from 406 consecutive allogeneic stem cell transplant recipients were analyzed retrospectively for EBV DNA with quantitative polymerase chain reaction (PCR). RESULTS: EBV DNA was found in the serum of 56 of the 406 patients (14%). EBV positivity was seen in 9 % of the recipients of a graft from a sibling donor and in 29 % of those with an unrelated donor. EBV-PCR positivity resolved without specific treatment in a third of the cases, in another third the copy number increased progressively or was high in the last serum sample, and in the remaining third the copy numbers were low in all positive sera including the last sample. In multivariate analysis antithymocyte globulin given for any reason and grade III-IV acute graft-versus-host disease were the only statistically significant risk factors for EBV reactivation. Only 8/56 patients with EBV-DNA positivity were alive at the time of the present analysis. The outcome of EBV-PCR positivity could not be predicted by the copy number or the timing of the first positive sample. INTERPRETATION AND CONCLUSIONS: EBV reactivation was a common phenomenon in allogenic stem cell transplant recipients. In many patients the viremia resolved without EBV-directed treatment. Severe acute graft-versus-host disease and antithymocyte globulin given for any reason were risk factors for EBV viremia.
BACKGROUND AND OBJECTIVES: An HLA-mismatched donor and a T-cell-depleted graft are known risk factors for Epstein-Barr virus (EBV) reactivation after stem cell transplantation. We studied the frequency and outcome of serum EBV DNA levels in patients transplanted with an unmanipulated graft from an HLA-identical donor. DESIGN AND METHODS: Overall, 5479 serial serum samples from 406 consecutive allogeneic stem cell transplant recipients were analyzed retrospectively for EBV DNA with quantitative polymerase chain reaction (PCR). RESULTS:EBV DNA was found in the serum of 56 of the 406 patients (14%). EBV positivity was seen in 9 % of the recipients of a graft from a sibling donor and in 29 % of those with an unrelated donor. EBV-PCR positivity resolved without specific treatment in a third of the cases, in another third the copy number increased progressively or was high in the last serum sample, and in the remaining third the copy numbers were low in all positive sera including the last sample. In multivariate analysis antithymocyte globulin given for any reason and grade III-IV acute graft-versus-host disease were the only statistically significant risk factors for EBV reactivation. Only 8/56 patients with EBV-DNA positivity were alive at the time of the present analysis. The outcome of EBV-PCR positivity could not be predicted by the copy number or the timing of the first positive sample. INTERPRETATION AND CONCLUSIONS:EBV reactivation was a common phenomenon in allogenic stem cell transplant recipients. In many patients the viremia resolved without EBV-directed treatment. Severe acute graft-versus-host disease and antithymocyte globulin given for any reason were risk factors for EBVviremia.
Authors: Sung W Choi; Patrick Stiff; Kenneth Cooke; James L M Ferrara; Thomas Braun; Carrie Kitko; Pavan Reddy; Gregory Yanik; Shin Mineishi; Sophie Paczesny; David Hanauer; Attaphol Pawarode; Edward Peres; Tulio Rodriguez; Scott Smith; John E Levine Journal: Biol Blood Marrow Transplant Date: 2012-03-30 Impact factor: 5.742
Authors: Jennifer A Kanakry; Aparna M Hegde; Christine M Durand; Allan B Massie; Amy E Greer; Richard F Ambinder; Alexandra Valsamakis Journal: Blood Date: 2016-01-07 Impact factor: 22.113
Authors: Hyoung Jin Kang; Keon Hee Yoo; Ji Won Lee; Hyery Kim; Soo Hyun Lee; Ki Woong Sung; Kyung Duk Park; Hong Hoe Koo; Hee Young Shin; Hyo Seop Ahn Journal: Ann Hematol Date: 2010-05-28 Impact factor: 3.673
Authors: Andrew H Walton; Jared T Muenzer; David Rasche; Jonathan S Boomer; Bryan Sato; Bernard H Brownstein; Alexandre Pachot; Terrence L Brooks; Elena Deych; William D Shannon; Jonathan M Green; Gregory A Storch; Richard S Hotchkiss Journal: PLoS One Date: 2014-06-11 Impact factor: 3.240
Authors: Pascal Roland Enok Bonong; Monica Zahreddine; Chantal Buteau; Michel Duval; Louise Laporte; Jacques Lacroix; Caroline Alfieri; Helen Trottier Journal: Vaccines (Basel) Date: 2021-03-19